News & Analysis as of

Therapeutic Goods Act

Ankura

eDiscovery and Life Sciences Industry - Challenges and Solutions

Ankura on

The life science industry is a significant contributor to the global market, with companies developing and manufacturing a wide range of medical products and devices. However, due to the complex and highly regulated processes...more

Hogan Lovells

Cell, tissue and gene therapies – Regulatory challenges and responses in Australia

Hogan Lovells on

Australian regulation of cell, tissue, and gene therapies (CTGT) is relatively new, with the regulatory framework for biological medical products first being introduced in 2011. A decade onwards, the Therapeutic Goods...more

Hogan Lovells

The ‘Anti-Trolling’ Bill: reassurance for social media page owners

Hogan Lovells on

The Federal Government has introduced the new Social Media (Anti-Trolling) Bill 2022 (Bill) which shifts publication liability from social media page owners to social media service providers (such as Facebook, Instagram and...more

Hogan Lovells

Failure to remove unlawful advertising attracts $12 million penalty

Hogan Lovells on

On 29 July 2021, the Federal Court of Australia (the “Court”) handed down its largest ever pecuniary penalty for serious, sustained and knowing contravention of the Therapeutic Goods Act 1989 (Cth) (“TG Act”). The decision...more

Hogan Lovells

Reforms to software-based medical devices take effect this week

Hogan Lovells on

The new classification rules for software-based medical devices (“SaMDs”) and personalised medical devices introduced by the Therapeutic Goods Legislation Amendment (2019 Measures No.1) Regulations 2019 commences this week,...more

Goodwin

Update on Biosimilar Launches and Development

Goodwin on

Biocon announced yesterday that it has received marketing authorization approval from the European Commission for Semglee™ (insulin glargine). The decision came after receiving a positive recommendation by the Committee for...more

6 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide